You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel pharmacogenomic approach for identifying T cell epitopes in replacement FVI

    SBC: Haplomics            Topic: NIMHD

    DESCRIPTION (provided by applicant): About 30% of congenital Hemophilia A (HA) patients develop alloantibodies that neutralize the activity of replacement Factor (F) VIII proteins. Among African American HA patients, the frequency of inhibitor formation ismuch higher; about 50%. Inhibitor patients are typically treated with bypassing agents. Bypassing agents are more expensive and less effective t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Cathepsin Inhibitors for Treatment of Breast Cancer Induced Bone Pain

    SBC: VIROBAY, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The World Health Organization estimates that the number of women living with breast cancer globally will rise to 15 million by the year 2020 with a significant portion of these patients in advanced stages of the disease. Breast cancer is the most frequent malignant tumor in women in the U.S. with nearly 200,000 women diagnosed each year. The U.S. NIH estimate o ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Amplification-free megabase target-enrichment for next-generation sequencing

    SBC: Mission Bio, Inc.            Topic: NHGRI

    DESCRIPTION (provided by applicant): Target enrichment for next-generation sequencing enables researchers to reduce the burden of sequence data analysis, obtain higher levels of statistical significance by examining more genomes and increase sequencing coverage depth. The goal of this STTR proposal is to develop and commercialize a novel technology capable of amplification-free megabase target seq ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. High Z Oraya Therapy for wet AMD

    SBC: ORAYA THERAPEUTICS, INC            Topic: NEI

    Project Description The purpose of this project is to develop a new radiotherapy treatment modality that will substantially enhance the treatment of wet AMD with minimal toxicity to healthy tissue, leading to major improvement in visual acuity, decreaseduse of intravitreal injections of anti-VEGF agents, lower cost of treatment, and a substantially improved quality of life for patients. The new m ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Identification and Quantification of Sequence Specific RNA Modifications via the Alpha-Hemolysin Latch Zone

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): During this STTR program, Electronic BioSciences (EBS) proposes to develop a nanopore based system around our University of Utah collaborators newly developed technology that will be capable of identifying and quantifying sequence specific RNA modifications. A system capable of quantitative, low cost, high throughput, RNA modification characterization has the c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Lateral Flow Immunoassays For Pharmacokinetic Dosing Of Monoclonal Antibodies

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Monoclonal antibodies (mAb) are used to treat a variety of cancers and other diseases. Dosing is typically based on body surface area, but population pharmacokinetic (PK) data suggests considerable variation across patients. Furthermore, there is growing evidence that patients with low final trough levels of circulating antibody have a poorer outcome, suggestin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Recombinant Botulinum Neurotoxin for Treatment of Spastic Disorders

    SBC: Cytodel, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Botulinum neurotoxin (BoNT) is the active ingredient in pharmaceutical products like Botox(R) (Allergan), which FDA has approved for therapeutic and aesthetic indications. Because of its inherent toxicity,the dose of BoNT required to treat spasticity disorders in large muscle groups is uncomfortably close to the toxic dose range. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of fluorescence-based receptor binding assays for the detection

    SBC: SeaTox Research Inc            Topic: NIEHS

    DESCRIPTION (provided by applicant): Harmful algal blooms (HABs) are becoming frequent occurrences off the coasts of the United States, particularly in coastal waters of New England, the Gulf of Mexico, and the Pacific Ocean. Historically, HABs have beenassociated with fish kills and marine mammal mortalities; however, their effects on human health and economic loss due to HAB contamination of se ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government